Navigation Links
BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome

- Project Combines Novel Gene Sequencing Chemistry and Advanced Nanofluidic Technology to Sequence Entire Human Genome in Eight Hours at a Cost of $100


PHILADELPHIA, and MOUNTAIN VIEW, Calif., Sept. 27 /PRNewswire/ -- BioNanomatrix, Inc., a company developing breakthrough nanoscale whole genome imaging and analytic platforms, and Complete Genomics Inc. (CGI), a high- performance genome sequencing company, today announced that they have formed a joint venture that has received an $8.8 million grant award from the U.S. National Institute of Standards and Technology Advanced Technology Program (NIST-ATP) to develop a system capable of sequencing the entire human genome in eight hours at a cost of less than $100.

"We and our colleagues at CGI are thrilled that NIST-ATP sees the potential of our combined technologies to achieve this ambitious goal," said Dr. Michael Boyce-Jacino, president and CEO of BioNanomatrix. "Our joint venture team will pool our innovative technologies--Complete Genomics' novel sequencing chemistry and our advanced nanofluidic platform--to develop a breakthrough technology that will radically decrease the cost and time required for sequencing the genome, making it possible for the first time for genetic information to be incorporated into routine medical care."

Today, the cost of sequencing the roughly three billion base pairs in the human genome is over $100,000. Despite advances that promise to reduce this cost significantly in the coming years, down to as little as $1,000 per individual, no one has previously targeted a price point that would make it possible to sequence everyone's genome. If successful, the $100 genome project could transform the role of genomics in medicine, making whole genome sequencing feasible for routine use in medical care and delivering far more diagnostic and predictive information than the genetic tests available today.

"We tried to approach this project from the perspective of the clinician, looking at the requirements and opportunities associated with incorporating genetics into routine clinical diagnostics," said Dr. Radoje (Rade) Drmanac, chief science officer and co-founder of Complete Genomics. "Accuracy, speed and low cost were paramount considerations. While there are a number of powerful and elegant sequencing strategies available or under development, we determined that we needed a completely novel approach to overcome their inherent limitations and achieve our $100 cost objective. We are optimistic that the combination of our two highly innovative approaches has a good chance of success. "

The joint venture has proposed adapting a novel DNA sequencing chemistry combined with linearized nanoscale DNA imaging to create a system that can "read" very long DNA sequences of greater than 100,000 bases at high speed and with accuracy exceeding the current industry standard. By condensing a wide range of genetic tests into a single, cost-effective platform, the proposed technology has the potential to enable improvements in the diagnosis and personalized treatment of a wide variety of health conditions, as well as the ability to deliver individually tailored preventive medicine. The $100 genome would also have important applications in medical research and drug development.

The NIST-ATP award is in the form of an $8.8 million matching grant for the five years of the project. The total project cost is expected to be approximately $17.8 million, including both the grant award from NIST-ATP and the matching funds that will be provided by the joint venture partners. Further details of the joint venture between BioNanomatrix and Complete Genomics were not disclosed.

About BioNanomatrix

BioNanomatrix is developing breakthrough nanoscale whole genome imaging and analytic platforms for applications in clinical genetics, cancer diagnostics and other biomedical applications. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single cell/single molecule level. BioNanomatrix' technologies are licensed exclusively from Princeton University. Founded as a spin-out of Princeton University in 2003, the company is headquartered in Philadelphia, Pennsylvania. For more information, visit:

About Complete Genomics

Complete Genomics Inc. (CGI) is a high-performance DNA sequencing company whose mission is to dramatically reduce the cost of DNA sequencing for research, drug development, and diagnostic applications. Founded in 2005, the company has developed a novel combination of high-density DNA nanoarrays, sequencing-by-hybridization and combinatorial probe-ligation chemistry, and high-performance computing techniques that promise to provide researchers and clinicians with fast, accurate, and inexpensive complete human genome sequencing. For more information, visit:


Barbara Lindheim

GendeLLindheim BioCom Partners

212 918-4650

SOURCE BioNanomatrix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. National Instruments DIAdem -- Complete Your Technical Data Management Framework with Powerful Off-line Analysis, Visualization, and Report Generation
2. Potawatomis complete acquisition of tech firm
3. Sonic Foundry completes $11.25M stock offer
4. Orion Energy completes $5M capital round
5. RedPrairie completes MARC acquisition
6. Metavante completes purchase of check processing firm
7. GE completes $1.2 billion acquisition
8. M & Is Metavante completes Brasfield Corp. acquisition
9. Berbee Data Centers complete audit, certification
10. Metavante completes GHR Systems acquisition
11. Metavante completes TREEV acquisition
Post Your Comments:
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... 23, 2016 adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):